STE50 Antibody

What is STE50 and why is it important for signaling pathway research?

STE50 functions as an essential adaptor protein that modulates multiple yeast MAPK signaling pathways, including the high-osmolarity glycerol (HOG) response pathway and the pheromone response pathway. It plays a crucial role by binding to STE11 (a MAPKKK) and facilitating its activation under various stress conditions. The STE50-STE11 interaction is absolutely required for signal transduction in the SHO1-STE11 branch of the HOG pathway, making it a critical target for understanding cellular stress responses .

Methodologically, studying STE50 requires specialized antibodies that can recognize its distinct domains and detect its interactions with binding partners. When designing experiments, researchers should consider both genetic approaches (using deletion mutants) and immunological approaches (using domain-specific antibodies) to comprehensively understand STE50's role in signaling networks.

What are the key structural domains of STE50 and how do they affect antibody selection?

STE50 contains two principal functional domains that researchers should consider when selecting antibodies:

• N-terminal domain (amino acids 68-118): This region specifically binds to the N-terminal domain of STE11 (residues 85-137) . Antibodies targeting this region are valuable for studying STE50-STE11 interactions.

• C-terminal RA (Ras Association) domain: This domain has functions similar to the mammalian N-terminal RA domain of Raf. It interacts with the membrane-anchored small Rho-like GTPase Cdc42 and the transmembrane protein Opy2p .

When selecting antibodies, researchers should consider which domain they wish to study. Domain-specific antibodies can help distinguish between STE50's roles in different signaling pathways, as the RA domain interactions are pathway-specific (Opy2p for HOG pathway, Cdc42p for filamentous growth pathway) .

How conserved is STE50 across species, and how does this affect antibody cross-reactivity?

STE50 contains structurally conserved domains, particularly the RA domain, which is found in signaling molecules across many eukaryotes . This conservation must be considered when selecting antibodies for cross-species experiments.

The search results do not provide specific data on cross-species reactivity of STE50 antibodies, but researchers should approach cross-species applications with caution. When using STE50 antibodies across different yeast species or other fungi, validation is crucial through Western blotting and immunoprecipitation against positive and negative controls to confirm specificity.

For cross-reactivity studies, researchers should consider:

• Sequence alignment analyses to identify conserved epitopes

• Validation experiments in each new species

• Use of multiple antibodies targeting different epitopes to confirm results

What phenotypes are observed in STE50 mutants and how can antibodies help characterize them?

STE50 mutants exhibit distinct phenotypes based on which signaling pathway is affected:

• HOG pathway mutants: Cells with mutations in the STE50 RA domain (particularly H275P) show specific HOG-signaling defects, resulting in osmosensitivity and inability to grow on high-salt media .

• Pheromone response mutants: Mutations in a specific surface region of the STE50-RA domain (opposite to the canonical binding site for small GTPases) cause defects in mating and response to pheromones .

• Filamentous growth pathway mutants: Mutations in residues I267 and L268 of the STE50-RA domain disrupt interaction with Cdc42p and affect filamentous growth .

Antibodies can help characterize these mutants through:

• Western blotting to verify protein expression levels

• Co-immunoprecipitation to assess disrupted protein interactions

• Immunofluorescence to examine subcellular localization changes

• Phospho-specific antibodies to monitor pathway activation states

How does the N-terminal STE11-binding domain of STE50 function, and what experimental approaches best characterize this interaction?

The STE50-STE11 interaction has been characterized using:

• Two-hybrid analysis: This approach mapped the interaction domains in both proteins .

• In vivo coprecipitation: GST-STE11 was shown to coprecipitate with both HA-STE50 and HA-STE50-N but not with STE50-C .

• Functional complementation tests: STE11 lacking the STE50-binding domain (STE11ΔSTE50BD) failed to restore growth of ssk2Δ ssk22Δ ste11Δ strains on sorbitol medium .

Antibody-based approaches for studying this interaction include:

• Co-immunoprecipitation with antibodies targeting either protein

• Proximity ligation assays to visualize interactions in situ

• FRET-based assays using antibodies conjugated with appropriate fluorophores

What are the optimal epitopes for generating specific STE50 antibodies?

When designing antibodies against STE50, researchers should consider targeting:

• The N-terminal STE11-binding domain (amino acids 68-118): Antibodies against this region can be used to study STE50-STE11 interactions .

• The C-terminal RA domain: Within this domain, specific regions mediate different pathway interactions:

  • Residues R274, H275, N276 for Opy2p interaction (HOG pathway)

  • Residues I267 and L268 for Cdc42p interaction (filamentous growth pathway)

  • A surface region opposite to the small GTPase binding site for pheromone response

Researchers should avoid highly conserved regions that might cross-react with other proteins containing SAM or RA domains, and instead target unique regions within these domains or linker regions between domains.

What controls are essential for validating STE50 antibody specificity?

For proper validation of STE50 antibodies, researchers should include:

• Positive controls:

  • Wild-type yeast expressing STE50

  • Recombinant STE50 protein or epitope-tagged STE50 (as demonstrated in the search results with HA-STE50)

• Negative controls:

  • ste50Δ deletion strains

  • Non-relevant proteins with similar structural domains

  • Pre-immune serum in immunostaining experiments

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Western blots against mutant variants with altered epitopes

  • Cross-adsorption tests against related proteins

The search results demonstrate validation approaches using GST-tagged STE11 and HA-tagged STE50 variants in coprecipitation experiments , which serve as a model for antibody validation strategies.

How do different fixation and sample preparation methods affect STE50 antibody performance?

Though the search results don't directly address fixation methods for STE50 antibodies, researchers working with yeast proteins should consider:

• For immunofluorescence:

  • Formaldehyde fixation (3-4%) preserves protein structure while allowing antibody access

  • Methanol fixation may improve access to some epitopes but can distort protein conformation

  • Spheroplasting with zymolyase before fixation improves antibody penetration through the yeast cell wall

• For biochemical studies:

  • Gentle lysis conditions preserve protein-protein interactions

  • Detergent selection is critical (typically NP-40 or Triton X-100 at 0.1-1%)

  • Protease and phosphatase inhibitors should be included to prevent protein degradation

• For co-immunoprecipitation:

  • Crosslinking may be necessary to capture transient interactions

  • Buffer conditions should be optimized to maintain native protein conformations

  • Pre-clearing lysates reduces non-specific binding

The search results demonstrate successful co-precipitation using GST-STE11 and HA-STE50 , suggesting these tagged proteins maintain their interaction under standard immunoprecipitation conditions.

What expression systems are most effective for producing recombinant STE50 for antibody generation?

While the search results don't specifically describe expression systems for recombinant STE50, they do mention using GST-STE11 and HA-STE50 in experimental systems . Based on this and standard practice for yeast proteins:

• Bacterial expression systems:

  • E. coli BL21(DE3) strains are commonly used for GST or His-tagged fusion proteins

  • Codon optimization may be necessary for efficient expression

  • Expression of separate domains may improve solubility compared to full-length protein

• Yeast expression systems:

  • S. cerevisiae or P. pastoris maintain native folding and modifications

  • Galactose-inducible promoters (GAL1) allow controlled expression

  • Epitope tags (HA, Myc, FLAG) facilitate purification and detection

• Insect cell systems:

  • Baculovirus expression systems may be useful for full-length protein with proper folding

  • Higher yields than yeast with many post-translational modifications preserved

When generating antibodies, consider using both full-length protein and peptides from specific domains to obtain a panel of antibodies with different specificities.

How can phospho-specific STE50 antibodies be developed to monitor pathway activation?

Although the search results don't specifically address phosphorylation of STE50, MAPK pathway proteins typically undergo phosphorylation during activation. For developing phospho-specific antibodies:

• Identify potential phosphorylation sites:

  • Analyze STE50 sequence for conserved MAPK phosphorylation motifs (S/T-P)

  • Consider sites near functional domains that might regulate interactions

  • Use mass spectrometry to identify phosphorylation sites in activated cells

• Generate phospho-specific antibodies:

  • Synthesize phosphopeptides containing the modification site plus flanking sequences

  • Use phosphopeptide for immunization and non-phosphopeptide for negative selection

  • Validate with phosphatase-treated samples as negative controls

• Validation strategies:

  • Compare antibody reactivity before and after pathway stimulation (e.g., osmotic stress)

  • Use phosphatase treatment to confirm specificity for phosphorylated form

  • Test specificity in phospho-site mutants (S/T to A mutations)

Phospho-specific antibodies could be particularly valuable for monitoring STE50's role in different signaling pathways under various stress conditions.

How can STE50 antibodies be used to study STE50-STE11 interactions in the HOG pathway?

STE50 antibodies can be powerful tools for studying STE50-STE11 interactions in the HOG pathway through several experimental approaches:

• Co-immunoprecipitation (Co-IP):

  • Precipitate STE50 using specific antibodies and probe for STE11 in the precipitate

  • Compare interactions under basal conditions versus osmotic stress

  • Analyze how mutations in the STE50BD region of STE11 (residues 85-137) affect interaction

• Proximity-based assays:

  • Proximity ligation assays (PLA) to visualize interactions in situ

  • FRET or BRET using fluorescently-labeled antibodies to monitor real-time interactions

• Chromatin immunoprecipitation (ChIP) approaches:

  • ChIP-reChIP to identify genomic regions where both proteins co-localize

  • Analyze recruitment to specific promoters during osmotic stress response

The search results demonstrate that wild-type STE11 restored growth of ssk2Δ ssk22Δ ste11Δ strains on sorbitol medium whereas STE11ΔSTE50BD did not , confirming the functional importance of this interaction. Antibodies can help determine whether this functional requirement reflects changes in binding, localization, or downstream activation.

What protocols are most effective for using STE50 antibodies in immunofluorescence microscopy?

For effective immunofluorescence with STE50 antibodies in yeast:

• Sample preparation:

  • Grow yeast to mid-log phase

  • Fix with 4% formaldehyde for 30-60 minutes

  • Digest cell wall with zymolyase to create spheroplasts

  • Permeabilize with 0.1% Triton X-100

• Immunostaining:

  • Block with 1% BSA or 5% normal serum

  • Incubate with primary STE50 antibody (1:100-1:500 dilution)

  • Wash extensively to remove unbound antibody

  • Apply fluorophore-conjugated secondary antibody

  • Counterstain with DAPI for nuclear visualization

• Controls and co-localization:

  • Include ste50Δ cells as negative controls

  • Use antibodies against known interaction partners (STE11, Opy2p, Cdc42) for co-localization

  • Perform Z-stack imaging to capture full three-dimensional distribution

Though not explicitly described in the search results, immunofluorescence would be valuable for testing hypotheses about STE50 localization. For example, the search results suggest that the RA domain of STE50 interacts with membrane-anchored proteins like Cdc42 and Opy2p to facilitate STE11 membrane localization , which could be directly visualized with immunofluorescence.

How can STE50 antibodies distinguish between different functional states of the protein in various MAPK pathways?

STE50 participates in multiple MAPK pathways with pathway-specific interactions. Antibodies can help distinguish these states through:

• Pathway-specific interaction partners:

  • Co-immunoprecipitate STE50 after specific pathway stimulation (e.g., osmotic stress for HOG, pheromone for mating)

  • Identify different binding partners using mass spectrometry

  • Compare interaction profiles between wild-type and pathway-specific mutants

• Domain-specific antibodies:

  • Use antibodies targeting the RA domain to monitor interactions with Opy2p (HOG pathway) or Cdc42p (filamentous growth)

  • Use N-terminal domain antibodies to assess STE11 binding across different conditions

• Conformational antibodies:

  • Develop antibodies that recognize specific conformational states of STE50

  • Use epitope mapping to identify antibodies that distinguish between different binding states

The search results identified pathway-specific mutations in the RA domain , suggesting that STE50 adopts different conformations or interaction patterns in different pathways. Domain-specific antibodies could help visualize these different functional states.

What quantitative assays can incorporate STE50 antibodies to measure pathway activation?

STE50 antibodies can be integrated into several quantitative assays to measure MAPK pathway activation:

• Quantitative Western blotting:

  • Measure STE50 phosphorylation status using phospho-specific antibodies

  • Quantify co-immunoprecipitated proteins as a measure of interaction strength

  • Compare protein levels and modifications across different stimulation conditions

• ELISA-based assays:

  • Sandwich ELISA using antibodies against STE50 and its binding partners

  • Competitive ELISA to measure specific interaction disruption

  • Phospho-ELISA to quantify pathway-specific phosphorylation events

• Flow cytometry:

  • Intracellular staining for STE50 and its modification states

  • Quantification of protein localization changes

  • Multiplex with other pathway components to assess correlation

• High-content imaging:

  • Automated quantification of STE50 localization

  • Correlation of STE50 distribution with cellular phenotypes

  • Real-time imaging of STE50 dynamics during stress response

The search results describe a quantitative mating assay to measure pathway function , which could be complemented with antibody-based approaches to directly measure the molecular events underlying the phenotypic changes.

How can chemical crosslinking be combined with STE50 antibodies to capture transient interactions?

Transient or weak interactions in MAPK pathways can be difficult to detect with standard co-immunoprecipitation. Combining chemical crosslinking with STE50 antibodies offers a solution:

• In vivo crosslinking approaches:

  • Treat cells with membrane-permeable crosslinkers (e.g., formaldehyde, DSP)

  • Use crosslinkers with different spacer arm lengths to capture various interaction distances

  • Apply optimized conditions to prevent over-crosslinking while capturing relevant interactions

• Immunoprecipitation of crosslinked complexes:

  • Lyse crosslinked cells under denaturing conditions to solubilize complexes

  • Immunoprecipitate with STE50 antibodies

  • Reverse crosslinks and identify interaction partners by Western blot or mass spectrometry

• Proximity-dependent biotinylation:

  • Express STE50 fused to BioID or TurboID

  • Allow proximity-dependent biotinylation of nearby proteins

  • Capture biotinylated proteins and identify using antibodies against known pathway components

While not explicitly covered in the search results, such approaches would be valuable for identifying the unknown pheromone pathway-specific interacting protein that was suggested to bind to the RA domain of STE50 .

How can domain-specific STE50 antibodies help resolve contradictions in experimental data?

Domain-specific antibodies against STE50 can be powerful tools for resolving experimental contradictions:

• Distinguishing direct versus indirect interactions:

  • Use domain-specific antibodies to determine which region of STE50 mediates a particular interaction

  • Compare binding patterns between full-length protein and isolated domains

  • Identify competitive binding scenarios where multiple partners interact with the same domain

• Resolving pathway crosstalk:

  • Use domain-specific antibodies to immunoprecipitate STE50 and determine which interactors are present under different stimulation conditions

  • Determine whether pathway-specific mutations affect interactions as predicted

• Testing structural predictions:

  • Use epitope-specific antibodies to test accessibility of regions in different conformational states

  • Verify domain exposure in different complexes

The search results identified pathway-specific regions in the RA domain of STE50 (e.g., H275P affecting HOG signaling specifically) . Domain-specific antibodies could help verify whether these mutations directly affect binding to predicted partners like Opy2p or have indirect effects on protein conformation.

What mass spectrometry approaches can be combined with STE50 immunoprecipitation to identify novel interaction partners?

Mass spectrometry combined with STE50 immunoprecipitation offers powerful ways to discover novel interaction partners:

• Standard IP-MS approaches:

  • Immunoprecipitate STE50 under different conditions (basal, osmotic stress, pheromone treatment)

  • Identify co-precipitated proteins by LC-MS/MS

  • Compare interactomes between conditions to identify pathway-specific interactions

• Crosslinking MS (XL-MS):

  • Apply crosslinkers to stabilize protein complexes

  • Immunoprecipitate STE50 complexes

  • Identify crosslinked peptides to map precise interaction interfaces

• Proximity-dependent methods:

  • Express STE50 fused to BioID or APEX2

  • Allow proximity-dependent labeling

  • Purify labeled proteins and identify by mass spectrometry

• Quantitative approaches:

  • Use SILAC or TMT labeling to quantitatively compare interactomes under different conditions

  • Apply for differential interaction analysis between wild-type and mutant STE50

These approaches would be particularly valuable for identifying the unknown pheromone pathway-specific protein that interacts with the RA domain of STE50 on the face opposite to the canonical binding site for small GTPases .

How can super-resolution microscopy be combined with STE50 antibodies to visualize signaling complexes?

Super-resolution microscopy with STE50 antibodies can reveal the nanoscale organization of signaling complexes:

• Sample preparation considerations:

  • Use high-affinity primary antibodies with minimal linkage error

  • Consider directly conjugated primary antibodies to reduce localization uncertainty

  • Use small fluorescent tags like Fab fragments or nanobodies when possible

• STORM/PALM approaches:

  • Apply photoswitchable dyes to antibodies against STE50 and interaction partners

  • Visualize nanoscale organization of signaling complexes

  • Perform multi-color imaging to map relative positions of different proteins

• SIM/STED approaches:

  • Use standard immunofluorescence protocols with bright, photostable dyes

  • Image membrane recruitment and clustering during pathway activation

  • Quantify colocalization at sub-diffraction resolution

• Expansion microscopy:

  • Physically expand samples to achieve super-resolution with standard confocal microscopy

  • Useful for thick yeast samples where optical super-resolution is challenging

Super-resolution approaches would be particularly valuable for testing hypotheses about STE50's role in facilitating STE11 membrane localization through interactions with membrane-anchored proteins like Cdc42 and Opy2p .

What CRISPR-based approaches can be combined with STE50 antibodies for functional genomics?

CRISPR technology can be combined with STE50 antibodies for functional genomics studies:

• Endogenous tagging:

  • Use CRISPR to introduce epitope tags at the endogenous STE50 locus

  • Create knock-in mutations corresponding to pathway-specific variants

  • Verify expression and localization with antibodies

• Domain-specific studies:

  • Generate domain deletion or replacement variants

  • Analyze effects on protein interactions and pathway activation

  • Use antibodies to confirm expression and localization

• Screening approaches:

  • Perform CRISPR screens for genes affecting STE50 function

  • Use antibodies to assess changes in STE50 localization, modification, or interactions

  • Identify novel pathway components

• Dynamic studies:

  • Create fluorescent protein fusions at endogenous loci

  • Combine with antibody-based staining of other pathway components

  • Analyze spatiotemporal dynamics of signaling complex assembly

While the search results used traditional yeast genetics approaches , CRISPR-based techniques would provide more precise genetic manipulation capabilities for studying STE50 function.

How can computational modeling be integrated with antibody-based experimental data to predict STE50 interaction dynamics?

Computational modeling can leverage antibody-based experimental data to predict STE50 interaction dynamics:

• Data integration approaches:

  • Use co-immunoprecipitation data to define interaction networks

  • Incorporate temporal data from time-course experiments

  • Add spatial information from immunofluorescence studies

• Structural modeling:

  • Build homology models of STE50 domains based on crystal structures

  • Dock interaction partners based on experimental constraints

  • Predict effects of mutations on binding interfaces

• Dynamic simulation:

  • Apply molecular dynamics simulations to predict conformational changes

  • Model pathway activation as a function of protein modifications

  • Simulate membrane recruitment and complex formation

• Machine learning approaches:

  • Train models on experimental data to predict outcomes of new mutations

  • Identify patterns in complex datasets that might not be apparent through direct analysis

  • Generate testable hypotheses for experimental validation

The search results provide structural information about the RA domain of STE50 and identify specific residues important for different pathway interactions , which could serve as constraints for computational models.

Why might STE50 antibodies show inconsistent results between different experimental conditions?

Several factors can cause inconsistent results with STE50 antibodies:

• Protein conformation changes:

  • STE50 may adopt different conformations in different signaling pathways

  • Epitopes may be masked in specific protein complexes

  • Solution: Use multiple antibodies targeting different epitopes

• Post-translational modifications:

  • Phosphorylation or other modifications may mask epitopes

  • Interactions with different partners in different pathways may protect specific regions

  • Solution: Use modification-insensitive antibodies or denaturing conditions

• Experimental variables:

  • Fixation methods can affect epitope accessibility differently for different interactions

  • Buffer conditions may stabilize certain interactions over others

  • Solution: Standardize protocols and validate under multiple conditions

• Expression level variations:

  • STE50 expression may change under different conditions

  • Solution: Quantify total protein by Western blot to normalize results

The search results demonstrate that specific mutations in the RA domain of STE50 affect different pathways , suggesting that STE50 adopts pathway-specific conformations that might affect antibody recognition.

What strategies can overcome weak signal problems when using STE50 antibodies?

To address weak signal problems with STE50 antibodies:

• Signal amplification methods:

  • Use tyramide signal amplification (TSA) for immunofluorescence

  • Apply poly-HRP secondary antibodies for Western blots

  • Consider biotin-streptavidin amplification systems

• Sample preparation optimization:

  • Increase protein concentration in lysates

  • Optimize extraction conditions to maximize solubility

  • Use epitope retrieval methods if applicable

• Antibody enhancement:

  • Use cocktails of antibodies targeting different epitopes

  • Try different antibody clones or sources

  • Consider directly conjugated primary antibodies to eliminate secondary antibody variability

• Detection system improvements:

  • Use more sensitive detection reagents (e.g., femto-level ECL substrates)

  • Apply longer exposure times with low-noise detection systems

  • Consider alternative detection platforms (e.g., Odyssey infrared system)

The research methods in the search results include approaches like two-hybrid analysis and in vivo coprecipitation , which could be complemented with these signal enhancement strategies for antibody-based detection.

How can specificity problems with STE50 antibodies be addressed and resolved?

To address specificity problems with STE50 antibodies:

• Validation controls:

  • Test antibodies in ste50Δ strains as negative controls

  • Compare reactivity across multiple antibodies targeting different epitopes

  • Perform peptide competition assays to confirm specificity

• Cross-reactivity reduction:

  • Pre-adsorb antibodies against lysates from ste50Δ strains

  • Use affinity-purified antibodies rather than crude serum

  • Apply more stringent washing conditions in immunoprecipitation and Western blots

• Alternative approaches:

  • Use epitope-tagged STE50 and tag-specific antibodies

  • Consider nano-bodies or aptamers for improved specificity

  • Apply CRISPR knock-in strategies to tag endogenous protein

• Advanced validation:

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

  • Compare binding patterns between antibodies targeting different epitopes

  • Validate with orthogonal methods like proximity labeling

The search results describe using specific mutations in the RA domain of STE50 to determine its role in different pathways , which could provide valuable negative controls for antibody validation.

What experimental design approaches can help resolve contradictory results between genetic and antibody-based studies?

To resolve contradictions between genetic and antibody-based studies:

The search results demonstrate how pathway-specific mutations in the RA domain of STE50 can differentially affect signaling , highlighting how mechanistic investigations can resolve seemingly contradictory results.

How should researchers interpret unexpected patterns of STE50 localization or interaction revealed by antibodies?

When facing unexpected antibody results:

• Verification strategies:

  • Confirm findings with multiple antibodies targeting different epitopes

  • Validate with orthogonal methods (e.g., fluorescent protein tagging)

  • Test under various fixation and permeabilization conditions

• Context interpretation:

  • Consider whether observed patterns occur in specific cellular compartments

  • Determine if patterns change under different stimulation conditions

  • Test if patterns correlate with functional readouts of pathway activity

• Dynamic perspective:

  • Examine time-course data to determine if observations represent transient states

  • Consider whether unexpected interactions might represent regulatory mechanisms

  • Test kinetics of association/dissociation under different conditions

• Hypothesis generation:

  • Use unexpected findings to formulate new mechanistic hypotheses

  • Design targeted experiments to test new models

  • Consider previously uncharacterized functions or interactions

The search results suggest that STE50 functions through multiple distinct interaction surfaces that mediate pathway-specific functions , which might explain unexpected localization or interaction patterns observed with antibodies.